Form 6-K PRANA BIOTECHNOLOGY LTD For: Sep 04

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR

15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of September 2018

 

Prana Biotechnology Limited

(Name of Registrant)

 

Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia.

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x                   Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨                      No x 

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____

 

This Form 6-K is being incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-199783) and Form S-8 (File No. 333-153669). 

 

 

PRANA BIOTECHNOLOGY LIMITED

 

6-K

Items

 

1.	Annual report 2018 on Form 20-F & XBRL data filed with SEC

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

	PRANA BIOTECHNOLOGY LIMITED
		(Registrant)
	By:	/s/ Geoffrey Kempler
		Geoffrey Kempler,
		Executive Chairman

  

September 4, 2018

 

 

 

  

MELBOURNE, AUSTRALIA September 3^rd 2018: Prana Biotechnology Ltd (ASX: PBT & NASDAQ: PRAN) announced that it has filed its Annual Report on Form 20-F containing audited consolidated financial statements for the year ended June 30, 2018 with the US Securities and Exchange Commission. The annual report is available on the Prana website (www.pranabio.com). Shareholders may receive a hard copy of the annual report free of charge upon request.

 

The Company has also filed the XBRL interactive data file with the US Securities and Exchange Commission, which is available via the company website at: http://pranabio.com/news/link-to-xbrl-interactive-data-30-june-2018#.W4yMF-gzaUl

 

Contacts:

 

Investor Relations	Media
Ben Walsh	Scott Newstead
E: [email protected]	E: [email protected]
Tp: +61 422 520 012	Tp: +61 3 9866 4722

 

For further information please visit the Company’s web site at www.pranabio.com.

 

Forward Looking Statements

 

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to any statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, PBT434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, PBT434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, PBT434, that could slow or prevent products coming to market, the uncertainty of patent protection for the Company's intellectual property or trade secrets, including, but not limited to, the intellectual property relating to PBT434, and other risks detailed from time to time in the filings the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management’s current expectations, but actual results may differ materially due to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Arbor Day Foundation’s ‘Canopy Report’ Examines How America Sees Trees
• Benson Hill Announces First Quarter Earnings Release Date
• PNOC FOUNDATION, A LEADING NON-PROFIT TO FURTHER ADVANCEMENTS IN PEDIATRIC BRAIN CANCER, ANNOUNCES FDA APPROVAL OF TOVORAFENIB (DAY101) IN PARTNERSHIP WITH PNOC SCIENTIFIC CONSORTIUM AND DAY ONE BIOPH